Semaglutide &
Cardiovascular
Outcomes
The SELECT trial — the largest cardiovascular outcomes trial ever run for a weight-loss drug — showed semaglutide reduces major cardiovascular events by 20% in people without diabetes. This guide explains what that means for you and your heart health.
The Science, Simplified
From landmark trial data to what it means for daily patients — this guide translates cutting-edge cardiology research into clear, actionable understanding.
GLP-1 receptors exist in cardiac tissue. This chapter explains the direct cardioprotective mechanisms — anti-inflammatory effects, reduced arterial stiffness, blood pressure lowering, and improved lipid profiles — separate from weight loss.
A deep-dive into the landmark 2023 SELECT trial: who was enrolled, what semaglutide dose was used, what the primary endpoints were, and exactly what the results showed — including the 20% reduction in MACE.
Earlier cardiovascular outcomes trials in people with type 2 diabetes that first established semaglutide's heart benefits — and how the results compare to the SELECT findings in people without diabetes.
Why patients with type 2 diabetes have 2-4× the cardiovascular risk of non-diabetic adults, the role of insulin resistance in coronary artery disease, and why GLP-1 mechanisms are uniquely well-suited to this population.
Not all GLP-1s have the same cardiovascular evidence profile. This chapter compares semaglutide, liraglutide, dulaglutide, and tirzepatide across their completed and ongoing cardiovascular outcome trials.
The SELECT trial enrolled highly selected patients. This chapter helps you understand how to interpret the findings for real-world patients — different ages, comorbidities, kidney function, and prior cardiac history.
Questions to ask your cardiac care team, how to discuss GLP-1 therapy in the context of your specific heart condition, and what your doctor needs to know before adjusting your regimen.
Ongoing cardiovascular trials (SOUL, FLOW, SURPASS-CVOT), the emerging evidence for heart failure, and what the next generation of GLP-1 medications may offer for cardiac patients.
This Guide Is For You If…
Get All 6 Guides for $69.99
This cardiovascular guide pairs perfectly with the Obesity & GLP-1, Discontinuation, Constipation Relief, Comfort, and Daily Pills guides.
Understand the Research.
Advocate for Your Heart.
The cardiovascular benefits of semaglutide are one of the most exciting developments in modern medicine. This guide puts that science in your hands.
For educational purposes only. Not medical advice. Always consult your cardiologist or healthcare provider before making changes to your treatment plan.